Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(66), 2022

DOI: 10.1128/aac.01657-21

Links

Tools

Export citation

Search in Google Scholar

Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa

Journal article published in 2022 by Lina Rivas, Manuel Alcalde-Rico, José R. W. Martínez, María Victoria Moreno, Pamela Rojas, Aniela Wozniak, Patricia García, Jorge Olivares-Pacheco, William R. Miller ORCID, Cesar A. Arias, Ayesha Khan ORCID, José M. Munita ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Ceftolozane/tazbactam (C/T) is a potent anti-pseudomonal agent that has clinical utility against infections caused by non-carbapenemase, producing-carbapenem-resistant Pseudomonas aeruginosa (non-CP-CR-PA). Accurate, precise, and reliable antimicrobial susceptibility testing (AST) is crucial to guide clinical decisions.